"It’s an amazingly clever move and will produce revenue short term and will expose the product to the US market." That's a good point. In my post I mentioned that early sales post FDA approval might be below 2% but a lower figure would likely experience stronger growth. The early access pre FDA approval will raise awareness in the US like it is starting to do here through experts in the field, clinics and of course through patients word of mouth. So when they do get FDA approval, first year's sales should be much stronger than they would have been without the early access to the market. A question for today's webinar; will they now pursue regulatory approval in other jurisdictions in parallel to the US and Australia?
LTP Price at posting:
43.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)